Imaging test for HER2 in metastatic cancer
Part of Cancer, Skin clinical trials.
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic (spread) cancer, either breast cancer or another solid tumor type.
- You have at least one tumor that shows up on a standard PET scan and is large enough (about the size of a grape) to biopsy.
- You are willing to have a biopsy of one of your tumors.
- You are not pregnant or breastfeeding, and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a drug called trastuzumab deruxtecan works in people with HER2-low breast cancer that has spread to other parts of the body. It uses PET-CT scans to check the tumor's response to treatment.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.